The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The $256,487 grant, effective August 13, 2024, supports a 5-year research project to develop multimodal predictive models for non-small cell lung cancer (NSCLC) using real-world data sources such as circulating tumor DNA sequencing, tumor genomics, and clinician notes. The goal is to improve risk stratification and clinical...
This $968,999 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a research study titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The study aims to optimize post-treatment surveillance for lung cancer survivors by incorporating risk-based strategies that leverage routinely available medical imaging data. The 5-year project, set...
The National Cancer Institute (NCI) awarded a $127,629 Project Grant (CFDA 93.398 - Cancer Research Manpower) to the President and Fellows of Harvard College, Harvard T.H. Chan School of Public Health, from February 1, 2025 to January 31, 2027. The grant will fund research to elucidate the role of germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor (ICI) monotherapy in patients with non-small cell lung cancer (NSCLC)....
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $858,166 to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The study aims to improve documentation of patients' end-of-life care preferences, delivery of end-of-life care, and participant-reported outcomes. The...
This $635,248 five-year Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development of a novel self-amplifying ribonucleic acid (SARNA) technology encoding a bispecific T-cell engaging (BiTE) antibody for the treatment of lung cancer. The key objectives are to: 1) design modified SARNA constructs expressing BiTE antibodies and evaluate their protein expression performance in vitro; 2) assess the in vitro/in vivo bioavailability and...
This $306,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is focused on developing an integrated machine learning framework to accurately identify lung cancer subtypes. The key products and services to be delivered include: Establishing a gene signature-transfer machine learning model that leverages large-scale bulk and single-cell transcriptomics data, both within and beyond NIH Common Fund...
This $662,516 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery in locally advanced head and neck and anaplastic thyroid cancers. The research will combine in vivo radiologic imaging, highly multiplexed microscopy, and functional perturbations on...
This Project Grant award of $730,398.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research aims to comprehensively characterize the lung cancer genomic landscape in patients of African ancestry. The key products and services to be delivered under this 5-year award include: Identifying and validating genomic differences between lung cancer patients of African and European ancestry, with a focus on drug targetable and...
The National Cancer Institute (NCI) awarded a $160,330 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the University of Illinois to develop novel human-relevant lung adenocarcinoma models. The two-year project aims to introduce oncogenic mutations into primary human lung stem and progenitor cells and generate organoid and xenograft models. The goal is to create models that better capture the initiation, progression, and composition of primary human lung adenocarcinoma...
The National Cancer Institute (NCI) awarded a $641,508 Cooperative Agreement grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The award, titled "ASPIRINS LEGACY ON CANCER AND OVERALL BENEFIT: RISK BALANCE OVER A 15-YEAR HORIZON", supports a research project focused on understanding and preventing cancer through a 15-year investigative effort. As a...
The National Cancer Institute (NCI) awarded a $238,824 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research aimed at optimizing lung cancer treatment decisions and improving quality-adjusted life years.
The key products and services to be delivered under this 18-month grant include: 1) Leveraging an ongoing cohort study of ~2,200 patients with stage I-III non-small cell lung cancer who underwent lymph node biopsy procedures (endobronchial ultrasound-guided transbronchial needle aspiration and mediastinoscopy) to assess how these procedures differentially impact treatment decisions (Aim 1); and 2) Simulating trials using decision analytic modeling to compare the quality-adjusted life years associated with the two biopsy procedures and any resulting treatment changes (Aim 2). The findings are expected to help harmonize national practice guidelines, direct quality improvement initiatives, and motivate future trials comparing patient-centered outcomes.